Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay)

被引：2

作者：

Hou, Yanjun ^{[1
]}

Tozbikian, Gary ^{[1
]}

Zynger, Debra L. ^{[1
]}

Li, Zaibo ^{[1
]}

机构：

[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave, Columbus, OH 43210 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2017年 / 147卷 / 06期

关键词：

Breast cancer; Estrogen receptor; Magee equation; Oncotype DX; Recurrence score; INVASIVE BREAST-CANCER; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PRIMARY TUMOR; PREDICT; PROGNOSIS; EXPRESSION; DECISIONS; PATHOLOGY; THERAPY;

D O I：

10.1093/AJCP/AQX008

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX. Methods: Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS. Results: The Pearson correlation coefficient (r) for the Magee equation and Oncotype DX RS was 0.6645 (P<.00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively. Conclusions: The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.

引用

页码：541 / 548

页数：8

共 35 条

[1] Expression of Forkhead- box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores [J].

Ademuyiwa, Foluso O. ;

Thorat, Mangesh A. ;

Jain, Rohit K. ;

Nakshatri, Harikrishna ;

Badve, Sunil .

MODERN PATHOLOGY, 2010, 23 (02) :270-275

[2] Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? [J].

Allison, K. H. ;

Kandalaft, P. L. ;

Sitlani, C. M. ;

Dintzis, S. M. ;

Gown, A. M. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :413-424

[3] Molecular Pathology of Breast Cancer What a Pathologist Needs to Know [J].

Allison, Kimberly H. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (06) :770-780

[4]

[Anonymous], BREAST CANC RES TREA

[5]

Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1

[6] Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation [J].

Biroschak, Julianne R. ;

Schwartz, Gordon F. ;

Palazzo, Juan P. ;

Toll, Adam D. ;

Brill, Kristin L. ;

Jaslow, Rebecca J. ;

Lee, Sun Yong .

BREAST JOURNAL, 2013, 19 (03) :269-275

[7] Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma [J].

Bomeisl, Philip E. ;

Thompson, Cheryl L. ;

Harris, Lyndsay N. ;

Gilmore, Hannah L. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) :1546-1549

[8]

Clark BZ, 2013, APPL IMMUNOHISTO M M, V21, P287, DOI 10.1097/PAI.0b013e31826f80c9

[9] Risk factors for breast cancer according to estrogen and progesterone receptor status [J].

Colditz, GA ;

Rosner, BA ;

Chen, WY ;

Holmes, MD ;

Hankinson, SE .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (03) :218-228

[10] Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer [J].

Cronin, Maureen ;

Sangli, Chithra ;

Liu, Mei-Lan ;

Pho, Mylan ;

Dutta, Debjani ;

Nguyen, Anhthu ;

Jeong, Jennie ;

Wu, Jenny ;

Langone, Kim Clark ;

Watson, Drew .

CLINICAL CHEMISTRY, 2007, 53 (06) :1084-1091

← 1 2 3 4 →